

Prof Angela Tincani
Professor Angela Tincani is a senior consultant (previously director) at the Rheumatology and Clinical Immunology Unit of Aziende Socio Sanitaria Territoriali (ASST)-Spedali Civili and University of Brescia, Italy.
Professor Tincani has been involved in several international committees for education and research in the field of systemic autoimmune diseases. Professor Tincani’s primary clinical and research interests include the use of anti-rheumatic drugs in pregnant and lactating patients and the management of pregnancy in rheumatic disease patients, in addition to evaluating autoantibodies and autoimmune diseases as risk factors for poor gestational outcomes. She served as an expert for several European Alliance of Associations for Rheumatology (EULAR) recommendations, including “Points to consider for use of anti-rheumatic drugs before pregnancy and during pregnancy and lactation”. Together with Professor Andreoli, Professor Tincani is co-principal investigator of the “Italian Registry of Pregnancy in Rheumatic Diseases”.
Achieving MDA or DAPSA treatment targets improves quality of life for patients with PsA.1–4 Explore the characteristics of patients who report treatment success...
ASDAS and BASDAI are commonly used in clinical practice.1,2 However, discover recent studies demonstrating that a high proportion of real-world patients do not...
Explore which treatment targets may be more appropriate for making treatment decisions in axSpA.
PsA and axSpA have overlapping disease manifestations which are driven by inflammation.1 Explore several extracellular cytokines that are implicated in these...
Watch Prof Frank Behrens discuss the importance of treating skin symptoms in addition to musculoskeletal symptoms for patients with SpA.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...